Insider Selling: Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $4,044,632.48 in Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 132,524 shares of the firm’s stock in a transaction dated Monday, October 26th. The shares were sold at an average price of $30.52, for a total value of $4,044,632.48. Following the transaction, the insider owned 167,438 shares in the company, valued at approximately $5,110,207.76. This trade represents a 44.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.59, for a total transaction of $4,525,301.06.
• On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total transaction of $3,924,676.63.
• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.89, for a total value of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The stock was sold at an average price of $26.34, for a total value of $1,988,880.72.
• On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.02, for a total value of $3,674.72.
• On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.73, for a total value of $4,812,181.01.

Alamar Biosciences Trading Up 5.1%

ALMR traded up $1.54 during midday trading on Tuesday, reaching $31.93. The company’s stock had a trading volume of 508,078 shares, compared to its average volume of 410,608. The company has a debt-to-equity ratio of 0.03, a quick ratio of 10.23 and a current ratio of 11.85. The firm has a fifty day simple moving average of $30.79. The stock has a market capitalization of $2.22 billion and a PE ratio of -16.29. Alamar Biosciences, Inc. has a twelve month low of $18.84 and a twelve month high of $39.61.

Alamar Biosciences (NASDAQ:ALMR) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. The business had revenue of $29.43 million for the quarter. Sell-side analysts expect that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on ALMR shares. TD Cowen reiterated a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. JPMorgan Chase & Co. increased their target price on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Weiss Ratings downgraded Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Finally, Stifel Nicolaus upped their price target on Alamar Biosciences from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $31.80.

Institutional Investors Weigh In On Alamar Biosciences

A number of institutional investors have recently bought and sold shares of the business. Braidwell LP acquired a new stake in Alamar Biosciences during the second quarter worth $29,365,000. Wellington Management Group LLP acquired a new position in shares of Alamar Biosciences in the 2nd quarter valued at $12,407,000. State Street Corp acquired a new position in shares of Alamar Biosciences in the 2nd quarter valued at $3,930,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Alamar Biosciences in the 2nd quarter valued at $283,000.

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.